SCHEMBL5492018

SCHEMBL5492018

NCCCCCCCCOc1ccc(O)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR5A1 Q13285 1/20 0.66
LTA4H P09960 2/20 0.56
ESR1 P03372 4/20 0.54
CYP19A1 P11511 4/20 0.54
ESR2 Q92731 4/20 0.54
ITGB3 P05106 1/20 0.53
ITGA2B P08514 1/20 0.53
F2 P00734 1/20 0.50
PLAU P00749 1/20 0.50
PRMT1 Q99873 1/20 0.50
ST14 Q9Y5Y6 1/20 0.50
ALDH2 P05091 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2A6 P11509 1/20 0.50
CYP3A5 P20815 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8765479 1.00 NR5A1 (0.66) NR5A1LTA4HESR1CYP19A1ESR2
SCHEMBL27827676 0.98 NR5A1 (0.62) NR5A1LTA4HESR1CYP19A1ESR2
SCHEMBL8766239 0.91 LTA4H (0.59) NR5A1LTA4HESR1CYP19A1ESR2
SCHEMBL16902828 0.89 NR5A1 (0.79) NR5A1LTA4HF2PLAUPRMT1
SCHEMBL1129755 0.89 NR5A1 (0.79) NR5A1LTA4HF2PLAUPRMT1
SCHEMBL6858863 0.89 NR5A1 (0.79) NR5A1LTA4HF2PLAUPRMT1
SCHEMBL8571102 0.89 NR5A1 (0.79) NR5A1LTA4HF2PLAUPRMT1
SCHEMBL11230467 0.89 NR5A1 (0.79) NR5A1LTA4HF2PLAUPRMT1
SCHEMBL16902827 0.89 NR5A1 (0.79) NR5A1LTA4HF2PLAUPRMT1
SCHEMBL9128116 0.89 NR5A1 (0.79) NR5A1LTA4HF2PLAUPRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US disclosed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP disclosed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO disclosed
EP-1453816-B1 PHENOXY AMINE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2013-09-18 EP disclosed
EP-1453816-B1 PHENOXY AMINE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2013-09-18 EP disclosed
US-7297794-B2 Phenoxy amine compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2007-11-20 US disclosed
US-7297794-B2 Phenoxy amine compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2007-11-20 US disclosed
US-7297794-B2 Phenoxy amine compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2007-11-20 US disclosed
US-20050119502-A1 Phenoxy amine compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2005-06-02 US disclosed
EP-1453816-A4 PHENOXY AMINE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2005-02-09 EP disclosed
EP-1453816-A2 PHENOXY AMINE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS Emisphere Technologies, Inc. (US) 2004-09-08 EP disclosed
WO-2003045306-A2 PHENOXY AMINE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119502-A1 Phenoxy amine compounds and compositions for delivering active agents PNMT, SLC5A7, PHOSPHO1 NR5A1 3184/4885LTA4H 2903/4885ESR1 1473/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 NR5A1 1411/4885LTA4H 320/4885ESR1 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.